Zobraziť v EDS

Elderly Patients with Newly Diagnosed Multiple Myeloma: Continuous or Fixed Duration Treatment?

Uložené v:
Podrobná bibliografia
Názov: Elderly Patients with Newly Diagnosed Multiple Myeloma: Continuous or Fixed Duration Treatment?
Autori: Salomon Manier, Thierry Facon
Zdroj: Hemato, Vol 5, Iss 2, Pp 115-118 (2024)
Informácie o vydavateľovi: MDPI AG, 2024.
Rok vydania: 2024
Predmety: multiple myeloma, safety, 0301 basic medicine, 03 medical and health sciences, 0302 clinical medicine, continuous treatment, Medicine, frailty assessment, elderly, 3. Good health
Popis: Multiple myeloma (MM) presents unique challenges in the elderly population due to increased frailty and comorbidities. Balancing treatment efficacy, safety, and quality of life is essential in managing elderly patients. While two-drug regimens were often favored for elderly patients, recent studies show promising outcomes with anti-CD38 antibody-based therapies, particularly daratumumab and lenalidomide with minimal dexamethasone. Continuous low-intensity treatments have shown improved progression-free survival and overall survival, with significant benefits observed in elderly patients. The DRd combination has now emerged as the standard of care for elderly MM patients, offering a favorable balance of efficacy, safety, and convenience. Ongoing trials are evaluating the addition of bortezomib in an induction phase for fit patients. New-generation immunotherapies hold promise for further refining treatment approaches, potentially leading to treatment discontinuation in select patient populations with sustained minimal residual disease negativity.
Druh dokumentu: Article
Jazyk: English
ISSN: 2673-6357
DOI: 10.3390/hemato5020010
Prístupová URL adresa: https://doaj.org/article/02570a2ecc484282a5ba8d7eee1161d5
Rights: CC BY
Prístupové číslo: edsair.doi.dedup.....6614b0700c5e35d17309d160be7f2d66
Databáza: OpenAIRE
Popis
Abstrakt:Multiple myeloma (MM) presents unique challenges in the elderly population due to increased frailty and comorbidities. Balancing treatment efficacy, safety, and quality of life is essential in managing elderly patients. While two-drug regimens were often favored for elderly patients, recent studies show promising outcomes with anti-CD38 antibody-based therapies, particularly daratumumab and lenalidomide with minimal dexamethasone. Continuous low-intensity treatments have shown improved progression-free survival and overall survival, with significant benefits observed in elderly patients. The DRd combination has now emerged as the standard of care for elderly MM patients, offering a favorable balance of efficacy, safety, and convenience. Ongoing trials are evaluating the addition of bortezomib in an induction phase for fit patients. New-generation immunotherapies hold promise for further refining treatment approaches, potentially leading to treatment discontinuation in select patient populations with sustained minimal residual disease negativity.
ISSN:26736357
DOI:10.3390/hemato5020010